Comparative Pharmacology
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus NAPROXEN SODIUM.
MECLOFENAMATE SODIUM vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID